001060 — JW Pharmaceutical Cashflow Statement
0.000.00%
- KR₩502bn
- KR₩521bn
- KR₩719bn
- 96
- 68
- 37
- 79
Annual cashflow statement for JW Pharmaceutical, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -15,275 | -1,441 | 29,853 | 38,430 | 65,040 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 28,243 | 56,357 | 51,780 | 64,558 | 24,692 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 29,399 | -52,903 | -41,704 | -38,406 | -29,441 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 63,054 | 18,124 | 56,764 | 87,157 | 79,392 |
| Capital Expenditures | -15,039 | -12,902 | -12,353 | -40,705 | -28,138 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -64,388 | -9,968 | -6,567 | -23,075 | 42,222 |
| Acquisition of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Sale of Intangible Assets | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -79,427 | -22,869 | -18,919 | -63,780 | 14,085 |
| Financing Cash Flow Items | — | — | — | -54 | -8,541 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -14,009 | 27,202 | -36,907 | -41,245 | -100,190 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -31,413 | 22,915 | 531 | -17,989 | -5,479 |